Literature DB >> 26796867

Effect of MRI Versus MDCT on Milan Criteria Scores and Liver Transplantation Eligibility.

Nassir Rostambeigi1, Andrew J Taylor1, Jafar Golzarian1, Eric H Jensen2, Timothy L Pruett2, Vikas Dudeja2, Donna D'Souza1.   

Abstract

OBJECTIVE: The Milan criteria for the selection of patients with hepatocellular carcinoma (HCC) for liver transplantation were originally based on the findings of contrast-enhanced CT examinations. Studies have shown improvement in HCC detection of using contrast-enhanced MRI instead of CT, but they have provided little information on the potential downstream effect on patient management that might result from discrepant imaging findings. We sought to assess the effect of discrepant imaging findings on patient eligibility to undergo liver transplantation.
MATERIALS AND METHODS: From 2006 to 2013, patients with a diagnosis of HCC who underwent both MDCT and MRI examinations within a 40-day period were studied retrospectively. All examinations were independently reviewed by two abdominal radiologists who recorded the number, diameter, and location of each lesion. Secondary confirmation of the lesions was made on the basis of histopathologic findings, diffusion restriction on DWI, increased T2 signal intensity, lesion growth, presence of fat, uptake of ethiodized oil, or a combination of these findings.
RESULTS: Sixty-four patients (48 men and 16 women; mean age, 62 years) met the criteria for inclusion in the study. Of the 129 lesions identified by MRI, only 102 of these lesions (79%) were identified by MDCT. This discrepancy led to a difference in the Milan criteria scoring for nine patients (14%). There was no statistically significant difference in the mean (± SD) greatest lesion diameter measured using the two modalities, with measurements of 3.52 ± 2.8 cm and 3.46 ± 2.8 cm noted on MDCT and MRI, respectively (p = 0.8). Lesions missed on MDCT studies tended to be smaller, with a mean diameter of 2.7 cm. Of the 129 lesions identified by MRI, 112 (87%) had available histopathologic findings or other confirmatory diagnostic evidence.
CONCLUSION: MDCT missed one-fifth of the HCC lesions detected by MRI. Had MDCT been the only imaging examination performed, failure to identify these lesions would have led to a different management plan for 14% of patients.

Entities:  

Keywords:  MRI; Milan criteria; hepatocellular carcinoma; liver transplantation

Mesh:

Substances:

Year:  2016        PMID: 26796867     DOI: 10.2214/AJR.15.14642

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

2.  Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation.

Authors:  Nieun Seo; Myoung Soo Kim; Mi-Suk Park; Jin-Young Choi; Chansik An; Kyunghwa Han; Seung Up Kim; Dong Jin Joo; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-07-04       Impact factor: 5.315

3.  Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?

Authors:  Mustafa Kurucay; Christopher Kloth; Sascha Kaufmann; Konstantin Nikolaou; Hans Bösmüller; Marius Horger; Wolfgang M Thaiss
Journal:  Cancer Imaging       Date:  2017-06-28       Impact factor: 3.909

Review 4.  Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review.

Authors:  Shamar Young; Andrew J Taylor; Tina Sanghvi
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

5.  MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma.

Authors:  Zhao-Hai Wang; Wei-Hu Wang; Xiao-Hang Wang; Liu-Hua Long; Yong Cui; Angela Y Jia; Xiang-Gao Zhu; Hong-Zhi Wang; Zhi Wang; Chong-Ming Zhan
Journal:  Br J Cancer       Date:  2020-01-15       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.